# DESCRIPTION

- introduce malaria as a serious disease
- describe current preventative medicines and their limitations
- highlight the need for an effective malaria vaccine
- discuss the strengths and weaknesses of current vaccine candidates
- motivate the use of irradiated sporozoites as a 'gold-standard' vaccine
- explain the challenges of identifying suitable protective liver-stage antigens
- describe the limitations of current small animal models of P. falciparum infection
- introduce LSA-1 as a promising liver-stage antigen
- summarize the results of clinical trials using LSA-1
- highlight the need for alternative antigens and delivery methods
- introduce the invention: antigenic compositions or vaccines comprising a viral vector
- describe the viral vector and its components
- explain the method of identifying key candidate antigens
- summarize the results of testing the efficacy of viral vectored vaccines
- highlight the identification of PfLSA1 as an exceptionally promising antigen
- define a protective immune response
- describe the variations of the nucleic acid sequence and peptide or protein sequence
- outline the composition and pharmaceutical composition of the invention
- list adjuvants
- describe nucleic acid encoding viral protein and Plasmodium protein
- provide multiple embodiments of nucleic acid encoding viral protein and Plasmodium protein
- describe virus comprising nucleic acid
- describe virus particle comprising Plasmodium protein
- provide multiple embodiments of virus particle comprising Plasmodium protein
- describe host cell comprising nucleic acid
- describe method of eliciting protective immune response
- describe method of prevention or treatment of malaria
- describe kit for vaccination regime against malaria
- describe method of manufacturing immunogenic composition or vaccine

## 1 MATERIALS AND METHODS

- list reagents
- describe solutions and buffers
- motivate antigen inserts
- analyze sequences
- modify sequences
- synthesize genes
- describe cloning into ChAd63
- outline PCR
- describe restriction cloning into ChAd63
- describe restriction cloning into MVA
- generate protein lysate
- describe PCR primer design
- outline PCR protocol
- detail transfection of HEK 293A cells
- describe harvest of cellular lysate
- genotype HHD mice
- describe adenovirus transfection and purification
- describe MVA transfection and purification
- outline animal handling and immunization procedures
- describe vaccine formulation and administration
- detail isolation of splenocytes and PBMCs
- describe isolation of liver mononuclear cells and primary murine hepatocytes
- describe liver dissection
- describe cell suspension preparation
- describe cell counting and viability determination
- describe cell plating and culture
- describe collection of mouse sera
- describe sera processing and storage
- introduce immunological assays
- describe peptide synthesis and preparation
- describe intracellular cytokine staining
- describe ELISpot assay
- describe isolation and adoptive transfer of CD4+ and CD8+ T cells
- describe enrichment of CD8+ T cells
- describe in vivo CD4+ or CD8+ T cell depletion
- describe luminescence immunoprecipitation assay
- describe enzyme-linked immunosorbent assay
- describe materials and methods
- detail whole IgG passive transfer
- introduce parasite strains
- describe preparation of thin blood smears
- outline sporozoite production
- detail cryopreservation of pRBCs
- describe sporozoite challenge
- outline in vivo imaging using IVIS system
- detail immunofluorescence antibody test
- describe murine in vitro T cell killing assay
- outline assessment of infectivity by flow cytometry

## 2 ASSESSING IMMUNOGENICITY AND EFFICACY OF EIGHT CANDIDATE P. FALCIPARUM VACCINES IN MICE

- introduce malaria vaccines
- motivate liver-stage malaria vaccines
- describe limitations of current vaccine trials
- introduce multi-parameter flow cytometry
- describe cytokine and marker assessment
- motivate functional immunogenicity assessment
- describe difficulties in assessing liver-stage malaria
- introduce transgenic P. berghei parasites
- describe vaccine efficacy assessment
- present cellular immune response results
- analyze CD8+ T cell-mediated response
- present antibody response results
- analyze fold change in antibody levels
- present vaccination efficacy results
- introduce P. falciparum and P. berghei protein sequences
- motivate cross-species protection
- describe ChAd63-MVA PfCe1TOS vaccination in Balb/c and C57BL/6 mice
- describe ChAd63-MVA PFI0580c vaccination in Balb/c mice
- describe ChAd63-MVA PfUIS3 vaccination in Balb/c mice
- summarize protective efficacy against heterologous P. berghei challenge
- introduce transgenic P. berghei parasites expressing P. falciparum antigens
- describe vaccination-challenge experiments in Balb/c mice
- present survival graphs for each transgenic parasite line
- summarize protective efficacy for each candidate antigen
- calculate median delay in time to 1% parasitaemia
- summarize immunogenicity and efficacy for each candidate antigen
- discuss immunogenicity and efficacy results
- confirm viral vectored vaccines express target antigens
- discuss IFNÎ³ response and CD8+ T cells
- discuss antibody responses
- discuss differences in immune responses between mouse strains
- discuss surprising lack of protection with ChAd63-MVA PfCe1TOS
- discuss protection with ChAd63-MVA PfUIS3 and PfLSA1
- summarize findings and implications for malaria vaccine development

## 3 ASSESSMENT OF PfUIS3, PfLSA1 AND PfLSAP2 AS CANDIDATES FOR A LIVER-STAGE MALARIA VACCINE

- introduce PfUIS3, PfLSA1 and PfLSAP2 as candidates
- motivate further assessment of these candidates
- describe experimental design for assessing protection in Balb/c mice
- present results of PfUIS3 vaccination in Balb/c mice
- analyze mechanism of protection of PfUIS3 vaccination
- describe experimental design for assessing protection in C57BL/6 mice
- present results of PfUIS3 vaccination in C57BL/6 mice
- describe experimental design for assessing protection in CD-1 outbred mice
- present results of PfUIS3 vaccination in CD-1 outbred mice
- present results of PfLSA1 vaccination in Balb/c mice
- analyze mechanism of protection of PfLSA1 vaccination
- present results of PfLSA1 vaccination in CD-1 outbred mice
- present results of PfLSAP2 vaccination in Balb/c mice
- analyze mechanism of protection of PfLSAP2 vaccination
- present results of PfLSAP2 vaccination in C57BL/6 mice
- present results of PfLSAP2 vaccination in CD-1 outbred mice
- compare protective efficacy of PfUIS3, PfLSA1 and PfLSAP2 vaccination

### 4. PROTECTIVE EFFICACY OF THE CANDIDATES VACCINES IN CD-1 OUTBRED MICE

- present results of PfLSA1 and PfLSAP2 vaccination in CD-1 outbred mice
- present results of PfUIS3, PfCSP and PfTRAP vaccination in CD-1 outbred mice

## 5. SUMMARY

- summarize results and implications for PfLSA1, PfUIS3, PfLSAP2 and PfI0580c as candidate vaccines

## 5. SPECT-1

- introduce SPECT-1 protein as a vaccine candidate

## 6. RESULTS

- design and generate PfSPECT-1 viral vector vaccines
- design and generate PfSPECT-1 expressing P. berghei chimeric parasites
- immunize and assess protective efficacy of PfSPECT-1 vaccine in mice
- assess blocking activity of serum from mice vaccinated with PfSPECT-1 viral vaccines
- analyze chimeric parasite fitness and liver loads in mice
- measure luminescence levels of Luciferase activity

